Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Forget Biosimilars: It's This Threat That Could Dent AbbVie's Top Line

By Todd Campbell - Jan 31, 2016 at 7:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A potential approval this year of a drug that may work better than Humira could imperil sales of the company's best-seller.

Source: Eli Lilly & Co.

Leading up to a key patent expiration on AbbVie's ( ABBV 2.10% ) top-selling drug Humira, investors are right to be a bit nervous about AbbVie's future. But it may not be the threat of biosimilar competition that crimps Humira's sales. Instead, it could be an FDA approval of Incyte Corporation ( INCY -1.17% ) and Eli Lilly & Co.'s ( LLY 0.30% ) rheumatoid arthritis drug baricitinib. Could baricitinib's positive clinical trial data cause doctors to prescribe it instead of Humira? Read on to find out more about baricitinib and its potential impact on AbbVie.

Defining the potential risk
Humira is the world's best-selling medicine. The drug is used to treat a variety of autoimmune diseases, and sales of Humira are running at an astonishing $14 billion annual clip.

Typically, having a mega-blockbuster in the product mix is a good thing, but Humira has been on the market since 2002, and its composition-of-matter patent expires at the end of 2016.

As a result, the potential for drugmakers to develop and launch generic biosimilars that aren't identical but work similarly to Humira has been a big worry for investors, because Humira accounts for more than 60% of AbbVie's top-line sales.

Source: AbbVie Inc.

Another emerging threat
The potential for biosimilars to eat away at Humira's market share shouldn't be ignored, but the threat may not be as close as investors think.

In Europe, approved biosimilars to other top-selling drugs have won away hundreds of millions of dollars in sales, and most industry watchers think that biosimilars will eventually capture 30%, or more, of branded biologics sales once patents expire.

However, AbbVie's composition-of-matter patent isn't the only patent protecting Humira, and AbbVie believes that its other patents, including method-of-use patents, could keep Humira biosimilars on the sidelines until the early 2020s.

If so, then the biosimilar threat isn't nearly as immediate as the potential threat that Incyte Corporation and Eli Lilly & Co.'s baricitinib poses. The two companies filed for FDA approval of baricitinib in January, and that means the drug could be on the market by the end of this year.

If approved, then trial results showing that baricitinib works better than Humira in some rheumatoid arthritis patients could mean baricitinib takes a healthy chunk out of Humira's revenue.

In phase 3 trials, baricitinib was superior to methotrexate in early RA, and it also improved symptoms in patients who don't respond to anti-TNFs such as Humira. Importantly, results also show that it's superior to Humira in treating patients who fail to improve on disease-modifying antirheumatic drugs (DMARDs), including the widely used methotrexate,

Since DMARD therapy is the mainstay in RA treatment, the potential to short-cut Humira's use when DMARDs fail could put baricitinib on a multibillion-dollar pace that comes at the expense of Humira. Given that Humira's 22% market share in the $18 billion rheumatoid arthritis market translates into roughly $4 billion per year in sales, there's a lot at stake.

Looking forward
There's no guarantee that baricitinib will win over FDA regulators or garner widespread support from doctors and patients, but if it does, then the payoff could be big to Eli Lilly, which owns global rights to baricitinib, and Incyte, which will collect royalties and milestones on baricitinib's sales.

Correspondingly, the risk of baricitinib's success to Humira could similarly be big enough that investors should keep close tabs on Eli Lilly and Incyte's progress. After all, it won't matter nearly as much if AbbVie can block biosimilars if competitors still strike a huge blow to Humira's sales. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$121.35 (2.10%) $2.50
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$246.33 (0.30%) $0.75
Incyte Corporation Stock Quote
Incyte Corporation
INCY
$65.01 (-1.17%) $0.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.